Diosmin in the treatment of venous disease: pharmacokinetics and pharmacodynamics

Talibov O.B.

doi:https://doi.org/10.17116/hirurgia2019031135

Talibov O.B.

Evdokimov Moscow State University of Medicine and Dentistry, Chair of Therapy, Clinical Pharmacology and Emergency Medical Care, Moscow, Russia

Diosmin in the treatment of venous disease: pharmacokinetics and pharmacodynamics

Authors:

Talibov O.B.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2019;(3): 135‑140

DOI: 10.17116/hirurgia2019031135

Read: 14140 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Talibov OB. Diosmin in the treatment of venous disease: pharmacokinetics and pharmacodynamics. Pirogov Russian Journal of Surgery. 2019;(3):135‑140. (In Russ.)
https://doi.org/10.17116/hirurgia2019031135

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

The Effect of Standardized Doses of Hesperidin and Diosmin on Venous Wall Remodeling in Patients with Primary Varicose Veins: a Prospective Controlled Study “STANDARD”. Journal of Venous Disorders. 2024;(4):293-301

Objective Monitoring of Compliance with Compression Treatment in Patients with Chronic Venous Disease is Better than Self-Reported Using Patient’s Diary. Journal of Venous Disorders. 2025;(2):113-119

Clinical Decisions in the Absence of Evidence: Expert’s Panel Recommendations for the Management of Chronic Venous Disease and Superficial Thrombophlebitis. Journal of Venous Disorders. 2025;(2):126-140

Onset, Time Course and Duration of Venoactive Drugs Effect on Venous Symptoms in Patients with Chronic Venous Disease. Journal of Venous Disorders. 2025;(3):206-215

Abstract:

The issues of absorption, bacterial intestinal metabolism and hepatic metabolism of diosmin are described. The main metabolites of the drug and the ways of their elimination are indicated. The article describes the main therapeutic targets and mechanisms of influence on the course of disease including effect on the venous wall tone and permeability, lymphatic drainage, inflammation and oxidative stress.

Keywords:

chronic venous disease

diosmin

diosmetin

hesperidin

pharmacokinetics

pharmacodynamics

Authors:

Talibov O.B.

Evdokimov Moscow State University of Medicine and Dentistry, Chair of Therapy, Clinical Pharmacology and Emergency Medical Care, Moscow, Russia

Close metadata

References:

Osterle OA, Wander G. HeIv Chim Acta. 1925;8:519-536.
Clark WG, Mackay EM. Effect of flavonoid (vitamin P-like) substances on histamine toxicity, anaphylactic shock, histamine-enhanced capillary permeability to dye, and bleeding time; with data on the toxicity of flavonoids. J Allergy. 1950 Mar;21(2):133-147.
Rutin to be commercially available for hypertension. Am Prof Pharm. 1946 Feb;12:146.
Warter PJ, Drezner HL, Horochak S. Effect of hesperidin and ascorbic acid on capillary fragility in rheumatoid arthritis; a preliminary report. J Med Soc N J. 1946 Jun;43:228-230.
de Tourris H, Kamina P, Allal A. Use of Diosmin in the heavy leg syndrome during the menopause. Bull Fed Soc Gynecol Obstet Lang Fr. 1971 Nov-Dec;23(5):586-588.
Berson I. About a new medicamentous treatment of the varicose syndrome (author’s transl). Schweiz Rundsch Med Prax. 1978 Jun 27;67(26):981-984.
Bashankaev BN, Wexner SD, Arkharov AV. Common sense of diosmin administration in combined treatment of hemorrhoids. Khirurgiia. Zhurnal im. Pirogova. 2018;8(Vyp. 2):83-89. (In Russ.)
Silvestro L, Tarcomnicu I, Dulea C, et al. Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans, using micro-liquid-chromatography-mass spectrometry and ion mobility mass spectrometry. Anal Bioanal Chem. 2013;405(25):8295-8310.
Garner RC, Garner JV, Gregory S, et al. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91(1):32-40.
Zhao M, Du L, Tao J, et al. Determination of metabolites of diosmetin-7-O-glucoside by a newly isolated Escherichia coli from human gut using UPLC-Q-TOF/MS. J Agric Food Chem. 2014;62 (47):11441-11448.
Spanakis M, Kasmas S, Niopas I. Simultaneous determination of the flavonoid aglycones diosmetin and hesperetin in human plasma and urine by a validated GC/MS method: in vivo metabolic reduction of diosmetin to hesperetin. Biomed Chromatogr. 2009 Feb;23(2):124-131.
Russo R, Chandradhara D, De Tommasi N. Comparative Bioavailability of Two Diosmin Formulations after Oral Administration to Healthy Volunteers. Molecules. 2018 Aug 29;23(9).
Cazaubon M, Bailly C, Ducros E, Lancrenon S. Etude comparative d’acceptabilité, d’efficacité et de tolérance de deux formes galéniques de diosmine 600 mg, dans le traitement des symptoms de la maladie veineuse chronique. Angéiologie. 2011;63:1-7.
Silvestro L, Tarcomnicu I, Dulea C, et al. Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans, using micro-liquid-chromatography-mass spectrometry and ion mobility mass spectrometry. Anal Bioanal Chem. 2013;405(25):8295-8310.
Cova D, De Angelis L, Giavarini F, et al. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1992;30(1):29-33.
Najmanová I, Pourová J, Vopršalová M, et al. Flavonoid metabolite 3-(3-hydroxyphenyl)propionic acid formed by human microflora decreases arterial blood pressure in rats. Mol Nutr Food Res. 2016;60(5):981-991.
Wang D, Ho L, Faith J, et al. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer’s disease β-amyloid oligomerization. Mol Nutr Food Res. 2015;59(6):1025-1040.
Araujo D, Viana F, Osswald W. Diosmin therapy alters the in vitro metabolism of noradrenaline by the varicose human saphenous vein. Pharmacol Res. 1991 Oct;24(3):253-256.
Savineau JP, Marthan R. Diosmin-induced increase in sensitivity to Ca2+ of the smooth muscle contractile apparatus in the rat isolated femoral vein. British Journal of Pharmacology. 1994;111(4):978-980.
Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg. 2000 Mar;31(3):456-461.
Imam F, et al. Diosmin downregulates the expression of T cell receptors, pro-inflammatory cytokines and NF-κB activation against LPS-induced acute lung injury in mice. Pharmacol Res. 2015 Dec;102:1-11.
Thebault JJ, Dormard Y. Dose/effect study in man with diosmin (venous tone & capillary resistance). International meeting on diosmin. 1984.